Thursday, June 11, 2026
← Back to archivePolicy
Policy•STAT News•Jun 11, 2026
Opinion: How long Covid’s scientific stalemate made it politically erasable
background ▾
- •Federal long Covid research infrastructure has been deliberately dismantled through grant terminations, advisory committee dissolution, and office closures, representing a major policy reversal with direct patient impact
- •The scientific community's inability to establish clear biomarkers and develop targeted interventions made long Covid vulnerable to political defunding, despite affecting millions of Americans
- •80% of dedicated post-Covid clinics have closed, forcing patients into primary care settings unprepared to manage the condition, with documented severe economic consequences (43% work cessation, 33% debt incurrence at one major clinic)
Policy•STAT News•Jun 10, 2026
OB-GYN association, deviating from CDC guidance, issues its own vaccine recommendations
background ▾
- •ACOG recommends routine administration of influenza and Covid-19 vaccines during pregnancy, directly contradicting withdrawn CDC recommendations under current HHS leadership
- •The split reflects a fundamental breakdown in CDC authority and expertise-driven vaccine policy, with professional medical societies establishing independent guidance to fill the vacuum
- •Pfizer's Abrysvo (RSV vaccine) market positioning is affected by the divergent guidance on booster schedules, with ACOG mirroring CDC's one-pregnancy limitation pending further data
PfizerAbrysvoTdapRSV vaccine
→ Read original articlePolicy•Fierce Pharma•Jun 11, 2026
Pfizer CEO Bourla reconsiders German investments as industry takes aim at healthcare reform plan: Reuters
background ▾
- •Pfizer CEO publicly escalates concerns about German healthcare reform by directly communicating with Chancellor Merz, indicating the plan poses meaningful business risks to the company
- •The pharma industry is collectively opposing the reform, suggesting sector-wide implications beyond a single company's operations
Pfizer
→ Read original articlePolicy•Fierce Pharma•Jun 11, 2026
AI medical advice changes care decisions of most users: survey
background ▾
- •Two-thirds of surveyed AI medical advice users acted on recommendations without physician consultation, indicating potential patient safety risks from unregulated health guidance
- •The trend suggests a regulatory gap: AI-generated medical advice currently lacks FDA or comparable oversight, creating liability and safety concerns for the pharmaceutical and healthcare industries
Policy•STAT News•Jun 11, 2026
Opinion: We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850
background ▾
- •The NIH's well-intentioned open-access mandate has inadvertently shifted publishing costs to researchers, with for-profit publishers charging $4,840–$12,850 per article to remove embargo periods on author-accepted manuscripts.
- •Springer Nature, Elsevier, and Wiley (controlling >7,500 journals) have refused to adopt zero-embargo policies and instead weaponized open-access fees to maintain revenue streams from federally funded research.
- •This creates a sustainability crisis for NIH-funded research teams: Ph.D. students publishing 3+ papers per degree and productive labs publishing dozens of papers annually now face thousands in publishing costs per paper, forcing difficult choices about journal selection and institutional budgets.
Springer NatureElsevierWiley
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jun 10, 2026
Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B
background ▾
- •Novartis commits $1.44 billion total value ($40M upfront + $1.4B milestones) to second Orionis deal, signaling deepened confidence in the molecular glue platform after initial 2020 collaboration
- •Molecular glue technology continues attracting major pharma investment across the sector (Eli Lilly-Magnet, Gilead-Kymera, Roche-Genentech partnerships noted), indicating class-wide validation
- •Watch for clinical readout timelines on Orionis pipeline candidates (ORB-011, ORB-021) and whether Novartis programs from this collaboration enter IND/clinical stages
NovartisOrionis BiosciencesRocheORB-011ORB-021
→ Read original articleMarket Access•Fierce Pharma•Jun 11, 2026
Eli Lilly yells ‘action’ on authentic patient portrayals at Tribeca Festival
background ▾
- •Eli Lilly is leveraging entertainment partnerships and film festivals as part of a patient advocacy and brand-building strategy
Eli Lilly
→ Read original articleMarket Access•Fierce Pharma•Jun 11, 2026
Teva to lay off 250 at API unit as search for new owner drags on: report
background ▾
- •Teva is reducing its CDMO workforce by 250 positions over 24 months as divestiture efforts continue
- •The layoffs suggest the CDMO sale process is taking longer than anticipated, prompting cost optimization
- •Outcome of the divestiture search and timing of a potential transaction remain uncertain
Teva Pharmaceutical
→ Read original articleMarket Access•Fierce Pharma•Jun 11, 2026
Genentech and Novartis dish up food allergy microdrama series
background ▾
- •Patient engagement and disease awareness campaign rather than a clinical or regulatory development
GenentechNovartis
→ Read original articleMarket Access•Endpoints News•Jun 10, 2026
Rare disease biotech Beren adds $300M from new financings
background ▾
- •Beren raised $300M in new capital to prepare for rare disease drug launch following pending FDA decision
- •Financing timing suggests company expects favorable regulatory outcome in fall 2024
Beren Therapeutics
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 10, 2026
Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza
background ▾
- •Ethyreal Bio's $101M funding and ETHY-001 anti-TSHR antibody represent a novel mechanistic approach to dual TED/GD treatment, differentiating from IGF-1R-focused competitors like Viridian's veligrotug
- •The TED/GD market is experiencing significant consolidation and competition with 8+ companies across multiple modalities, suggesting substantial perceived commercial opportunity but increasing clinical and commercial risk
- •Watch for Endocrine Society 2026 meeting data on ETHY-001 preclinical efficacy, Viridian's FDA decision outcome, and clinical readouts from other TSHR antagonist programs to clarify competitive positioning
Ethyreal BioAmgenAtlas VentureETHY-001Tepezzaveligrotug
→ Read original articleClinical Trials•Fierce Biotech•Jun 10, 2026
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
background ▾
- •SonoThera's microbubble-ultrasound platform enables delivery of full-length dystrophin gene (13+ kb) to DMD patients—a payload 3x larger than current AAV vectors can accommodate, positioning it as potentially the only approach attempting full-length dystrophin delivery.
- •Significant pharma validation: four major pharmaceutical venture arms (UCB, Bayer, Otsuka, J&J) co-invested, indicating industry recognition of the platform's potential to solve critical delivery constraints limiting current gene therapy applications.
- •Watch for: DMD clinical trial initiation in 2024 and early efficacy/safety data; regulatory pathway clarity for novel ultrasound-based delivery; competitive positioning against Sarepta's shortened-gene approaches and emerging in vivo gene editing platforms.
SonoTheraVida VenturesUCB (Union Chimique Belge)Elevidysdystrophin gene therapy (full-length, SonoThera)
→ Read original articleClinical Trials•Fierce Biotech•Jun 10, 2026
ADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisons
background ▾
- •CagriSema demonstrated inferior weight loss (23%) versus retatrutide (28-30%) at ADA, marking a significant efficacy gap that Novo acknowledges but attributes to incomplete trial data
- •CagriSema showed superior HbA1c reduction in Type 2 diabetes (1.91% vs retatrutide's ~1.9%), suggesting potential differentiation in the diabetes-focused segment
- •Novo's Redefine 11 trial outcome is critical to watch—the company expects higher weight loss data that could narrow the competitive gap with retatrutide
Novo NordiskEli LillyRBC Capital MarketsCagriSemacagrilintidesemaglutide
→ Read original articleClinical Trials•Fierce Biotech•Jun 10, 2026
GLP-1s may combat depression by multiplying a mood-boosting gut microbe
background ▾
- •GLP-1 drugs may exert antidepressant effects via a gut-microbiome pathway independent of GLP-1 receptor activation in the brain, explaining conflicting clinical observations about their psychiatric effects.
- •The mechanism involves GLP-1-mediated proliferation of L. delbrueckii bacteria and production of 2-AG, with preclinical evidence of symptom improvement in depressed mice.
- •Human clinical trials will be needed to validate this gut-brain pathway and determine whether it explains variable psychiatric outcomes observed in GLP-1 patients; Novo Nordisk and Eli Lilly have not yet engaged with the research team.
Novo NordiskEli Lillyliraglutidesemaglutidetirzepatide
→ Read original articleClinical Trials•Endpoints News•Jun 10, 2026
SonoThera raises $125M for non-viral gene therapy approach
background ▾
- •SonoThera has secured substantial Series B capital ($125M) to advance a novel non-viral ultrasound gene delivery approach, addressing a key technical challenge in gene therapy
- •The company's focus on Duchenne muscular dystrophy represents a high-value indication with significant unmet need and regulatory pathways for rare disease designation
SonoThera
→ Read original article